Israel - inglés - Ministry of Health

teva israel ltd - deferasirox - tablets dispersible - deferasirox 125 mg - deferasirox - deferasirox teva is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic] ≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg /l).lic is the preferred method of iron overload determination and should be used wherever available.

Israel - inglés - Ministry of Health

teva israel ltd - deferasirox - tablets dispersible - deferasirox 250 mg - deferasirox - deferasirox teva is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic] ≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg /l).lic is the preferred method of iron overload determination and should be used wherever available.

Israel - inglés - Ministry of Health

teva israel ltd - deferasirox - tablets dispersible - deferasirox 500 mg - deferasirox - deferasirox teva is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic] ≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg /l).lic is the preferred method of iron overload determination and should be used wherever available.

Israel - inglés - Ministry of Health

teva israel ltd - teriflunomide - film coated tablets - teriflunomide 14 mg - teriflunomide - teriflunomide teva is indicated for the treatment of adult patients with relapsing remitting forms of multiple sclerosis (ms) to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Israel - inglés - Ministry of Health

teva israel ltd - letrozole - tablets - letrozole 2.5 mg - letrozole - letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Israel - inglés - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 10 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - inglés - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 15 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - inglés - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 2.5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - inglés - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 20 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - inglés - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 25 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.